Shares of Ironwood Pharmaceuticals (IRWD) added ~31% on Friday to hit a new 52-week high after the company set its 2026 revenue outlook ahead of Street forecasts, citing higher net sales from Linzess, ...

- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - - Ended Q4 2025 with greater ...

1 Ironwood’s U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood’s commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue ...

Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) stock rose Friday with a session volume of 38.35 million compared to the average volume of 2.36 million, as per data from Benzinga Pro. The ...

(RTTNews) - Ironwood Pharmaceuticals (IRWD), a commercial-stage biotechnology company, today provided guidance for fiscal year 2026, while reaffirming its 2025 outlook, sending the shares to a new ...

Ironwood Pharmaceuticals expects revenue to rise next year, boosted in part by higher sales of Linzess, its drug used to treat irritable bowel syndrome and constipation. The Boston biotechnology ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Shares of Ironwood ...

・The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026. ・U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November. ・Linzess ...

The City Council on Thursday signed off on Mayor Eric Adams’ “City of Yes” plan, paving the way for more housing in the five boroughs. The Council approved the plan by a vote of 31 to 20, two weeks ...

U.S. stocks were higher, with the Nasdaq Composite gaining more than 1% on Friday. Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) rose sharply during Friday's session after the company issued ...